Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review.
A small percentage (1-10%) of renal cell carcinomas (RCC) belongs to the sarcomatoid variant. These malignancies are aggressive with worse prognosis and unfortunately the results following immuno- and/or chemotherapy administration are discouraging. A 62-year-old Caucasian male with advanced renal cell cancer and sarcomatoid component treated with sunitinib is presented. Better understanding of prognostic and molecular markers might help the selection of patients with a chance of benefiting from administration of new targeted drugs.
Kountourakis
P
P
First Department of Medical Oncology, Ag. Savvas Anticancer Hospital, Athens, Greece. pantkount@hotmail.com
Kandylis
K
K
Daskalopoulou
D
D
Rigatos
G
G
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology*; D002454:Cell Differentiation; D017809:Fatal Outcome; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy / Q000473:pathology*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib